Primary Myelofibrosis
What is Primary Myelofibrosis?
Primary myelofibrosis is a rare blood disorder that affects your bone marrow. Your bone marrow is the spongy tissue inside your bones that makes blood cells. In this condition, the bone marrow gets replaced by fibrous scar tissue instead of healthy cells. This scarring makes it hard for your body to produce normal red blood cells, white blood cells, and platelets.
As the condition progresses, your spleen often grows larger to help make blood cells. This type of disorder is called a myeloproliferative neoplasm. It means your bone marrow makes too many of certain blood cells at first, but the scarring eventually reduces blood cell production. Primary myelofibrosis typically develops slowly over many years. It affects about 1 in every 100,000 people and usually appears in adults over age 60.
About 50 to 60 percent of people with primary myelofibrosis have a specific genetic change called the JAK2 V617F mutation. This mutation makes cell signaling become overactive, which leads to the excessive fibrous tissue buildup. Finding this mutation through blood testing helps confirm the diagnosis and guide treatment decisions.
Symptoms
- Feeling very tired or weak, even after rest
- Shortness of breath during normal activities
- Pale skin due to low red blood cell counts
- Easy bruising or unusual bleeding
- Frequent infections from low white blood cell counts
- Pain or fullness in the left upper belly from enlarged spleen
- Fever without infection
- Night sweats that soak your clothes or sheets
- Unintentional weight loss over several months
- Bone pain, especially in the legs
Some people have no symptoms in the early stages of primary myelofibrosis. The condition may be discovered during routine blood tests done for other reasons. Symptoms typically develop gradually as scarring increases and blood cell production becomes more impaired.
Concerned about Primary Myelofibrosis? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
Primary myelofibrosis happens when bone marrow cells develop genetic mutations that make them grow and divide abnormally. The most common mutation is JAK2 V617F, found in 50 to 60 percent of cases. Other mutations include CALR and MPL genes. These mutations cause overactive cell signaling, which tells the bone marrow to produce too many abnormal cells and fibrous scar tissue. Scientists do not fully understand what triggers these genetic changes to occur.
Risk factors include age over 60, exposure to certain industrial chemicals like benzene or toluene, and previous radiation exposure. Men have a slightly higher risk than women. The condition is not inherited in most cases, though rare families show clustering. Having another blood disorder like polycythemia vera or essential thrombocythemia can sometimes progress to myelofibrosis over time. Lifestyle factors do not directly cause this condition, but maintaining overall health supports better outcomes during treatment.
How it's diagnosed
Diagnosis starts with a complete blood count and blood smear to check your blood cell levels and appearance. Your doctor will look at platelet count, which can be high in early stages or low in advanced disease. Testing for the JAK2 V617F mutation helps confirm the diagnosis in about half of all cases. Basophil levels may also be elevated, as this occurs in 30 to 40 percent of people with primary myelofibrosis. Rite Aid's testing panel includes platelet count, basophils, and JAK2 V617F mutation analysis to help detect and monitor this condition.
Your doctor will likely also perform a bone marrow biopsy to examine the scar tissue directly. Imaging tests like ultrasound can measure your spleen size. Genetic testing for additional mutations may be needed. Early detection through blood testing helps doctors start treatment sooner and monitor disease progression more effectively.
Treatment options
- JAK inhibitor medications like ruxolitinib to reduce spleen size and symptoms
- Blood transfusions when red blood cell counts drop too low
- Medications to reduce high platelet counts if needed
- Immunomodulatory drugs like thalidomide or lenalidomide for anemia
- Androgens to stimulate red blood cell production
- Spleen removal surgery if the spleen becomes dangerously enlarged
- Stem cell transplant for younger, healthier patients as the only potential cure
- Regular blood tests to monitor cell counts and disease progression
- Good nutrition to support energy levels and immune function
- Staying active within your energy limits to maintain strength
Concerned about Primary Myelofibrosis? Get tested at Rite Aid.
- Simple blood draw at your nearest lab
- Results in days, not weeks
- Share results with your doctor
Frequently asked questions
Life expectancy varies widely based on several factors including age, symptom severity, and genetic markers. Some people live many years with good quality of life, while others have more aggressive disease. Risk scoring systems help doctors predict outcomes. Early detection and proper treatment significantly improve survival and quality of life.
Yes, blood tests are essential for detecting this condition. Testing checks platelet count, basophil levels, and the JAK2 V617F mutation. About 50 to 60 percent of people with primary myelofibrosis test positive for the JAK2 mutation. Abnormal platelet and basophil counts also provide important diagnostic clues.
Yes, primary myelofibrosis is classified as a type of blood cancer called a myeloproliferative neoplasm. The bone marrow produces abnormal cells that lead to scarring. However, it behaves differently than other cancers and progresses slowly in many cases. Treatment focuses on managing symptoms and slowing disease progression.
As bone marrow becomes scarred and cannot make enough blood cells, the spleen tries to compensate by producing blood cells. This extra work causes the spleen to grow much larger than normal. An enlarged spleen can cause belly pain and fullness. Medications and sometimes surgery help manage spleen enlargement.
Your doctor will recommend a monitoring schedule based on your disease stage and symptoms. Many people need blood tests every 3 to 6 months to check cell counts and track disease progression. More frequent testing may be needed if you start new treatments. Regular monitoring helps catch changes early.
Stem cell transplant is currently the only treatment that can potentially cure primary myelofibrosis. However, this procedure carries significant risks and is typically reserved for younger, healthier patients. For most people, treatment focuses on managing symptoms, slowing progression, and maintaining quality of life with medications and supportive care.
JAK2 V617F is a genetic mutation found in 50 to 60 percent of people with primary myelofibrosis. This mutation causes overactive cell signaling in bone marrow, leading to abnormal cell growth and scarring. Testing for this mutation helps confirm diagnosis and guides treatment decisions. JAK inhibitor medications specifically target this pathway.
Many people with primary myelofibrosis eventually need blood transfusions as the condition progresses. Low red blood cell counts cause severe fatigue and other symptoms. Transfusions provide temporary relief by replacing red blood cells. The frequency depends on how low your counts drop and how well other treatments work.
While lifestyle changes cannot cure this condition, they support overall health during treatment. Eating nutritious foods helps maintain energy and immune function. Gentle exercise within your limits preserves strength and mood. Avoiding infections through good hygiene matters since immune function may be impaired. Work closely with your medical team.
Primary myelofibrosis develops on its own without another blood disorder coming first. Secondary myelofibrosis occurs when another condition like polycythemia vera or essential thrombocythemia transforms over time. Both types cause bone marrow scarring and similar symptoms. Blood tests and bone marrow examination help distinguish between them.